Background: Previous studies have described apoptosis in the stratum granulosum and in the stratum corneum, but not in the germinative compartment in normal skin. In psoriasis, an increased epidermal apoptosis has been observed in the differentiated compartment, suggesting that apoptosis has a key role in the pathogenesis of psoriasis, as a counteracting factor to the overproduction of cells. Little is known on apoptosis in the germinative compartment. Methods: Apoptosis was studied on biopsies of normal skin, established lesions of psoriasis and PUVA-treated psoriasis using the transferase-mediated uridine nick end labelling method, which detects fragmented DNA, and electron microscopy. Counting of apoptotic cells was restricted to the germinative compartment as defined by Mib1 staining to evaluate the impact of cell loss on cell production and tissue architecture. Results: The apoptotic index was 0.12% in normal epidermis, 0.035% in established psoriasis and 0.31% in regressive psoriasis. Conclusion: These results have three implications: (1) they show the physiological presence of apoptosis in the germinative compartment in normal epidermis; (2) they suggest that induction of apoptosis is involved in the regression of psoriatic hyperplasia after PUVA therapy; (3) the decrease of physiological apoptosis in the psoriatic lesion suggests that this phenomenon could play a role in the induction of psoriatic hyperplasia.

Keywords:
Apoptosis, Epidermis, Psoriasis
1.
Haake AR, Polakowska RR: Cell death by apoptosis in epidermal biology. J Invest Dermatol 1993;101:107–112.
2.
Budtz PE: Expectations of human epidermal kinetic homeostasis. Br J Dermatol 1986;114:645–650.
3.
Weedon D: Apoptosis. Adv Dermatol 1990;5:243–256.
4.
Gavrieli Y, Sherman Y, Ben-Sasson SA: Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992;119:493–501.
5.
McCall CA, Cohen JJ: Programmed cell death in terminally differentiating keratinocytes: Role of endogenous endonuclease. J Invest Dermatol 1991;97:111–114.
6.
Tamada Y, Takama H, Kitamura T, Yokochi K, Nitta Y, Ikeya T, Matsumoto Y: Identification of programmed cell death in normal skin tissues by using specific labelling of fragmented DNA. Br J Dermatol 1994;131:521–524.
7.
Weedon D, Strutton G: Apoptosis as the mechanism of the involution of hair follicles in catagen transformation. Acta Derm Venereol (Stockh) 1981;61:335–339.
8.
Potten CS: Cell death (apoptosis) in hair follicles and consequent changes in the width of hairs after irradiation of growing follicles. Int J Radiat Biol Relat Stud Phys Chem Med 1985;48:349–360.
9.
Bianchi L, Farrace MG, Nini G, Piacentini M: Abnormal BCL2 and ‘tissue’ transglutaminase expression in psoriatic skin. J Invest Dermatol 1994;103:829–833.
10.
Reincnyk E, Thomazy V, Davies PJA, Duvic M: Increased apoptosis in psoriasis. Cell Biol Int 1994;18:528.
11.
Mitra RS, Wrone-Smith T, Simoniaw P, Foreman KG, Nunez G, Nickoloff BJ: Apoptosis in keratinocytes is not dependent on induction of differentiation. Lab Invest 1997;76:99–107.
12.
Wyllie AH, Kerr JFR, Currie AR: Cell death: The significance of apoptosis. Int Rev Cytol 1980;68:251–306.
13.
Heenen M, Thiriar S, Noel JC, Galand P: Ki-67 immunostaining of normal human epidermis: Comparison with 3H-thymidine labelling and PCNA immunostaining. Dermatology 1998;197:123–126.
14.
Karnovsky MJ: A formaldehyde glutaraldehyde fixative of high osmolality for use in electron microscopy. J Cell Biol 1965;27:137A.
15.
Iseki S: DNA strand breaks in rat tissues as detected by in situ nick translation. Exp Cell Res 1986;167:311–326.
16.
Linser I, Aubock J, Romani N, Smolle J, Grubauer G, Fritsch P, Hinter H: The keratin body phenomenon. Epithelia 1987;1:85–99.
17.
Goodwin P, Hamilton S, Fry L: Comparison between DNA synthesis and mitosis in uninvolved and involved psoriatic epidermis and normal epidermis. Br J Dermatol 1973;89:619–628.
18.
Ralfs I, Dawber, Ryan T, Duffill M, Wright NA: The kinetics of metaphase arrest in human psoriatic epidermis: An examination of optimal experimental conditions for determining the birth rate. Br J Dermatol 1981;104:231–242.
19.
Young AR: The sunburn cell. Photodermatology 1987;4:127–134.
20.
Heenen M, Galand P, De Maertelaer V, Heenen PH: Psoriasis: Hyperproliferation cannot induce characteristic epidermal morphology. Cell Tissue Kinet 1987;20:561–570.
21.
Wright N, Alison M: The theory of renewing cell populations; in Wright N, Alison M (eds): The Biology of Epithelial Cell Population. Oxford, Clarendon Press, 1984, vol I.
22.
Bursch W, Kleine K, Tenniswood M: The biochemistry of cell death by apoptosis. Biochem Cell Biol 1990;68:1071–1074.
23.
Sepp N, Linser I, Hintner H, Fritsch P: Disturbed epidermal homeostasis in psoriasis. J Invest Dermatol 1990;95:488.
24.
Wrone-Smith T, Johnson T, Nelson B, Boise LH, Thompson CB, Nunez G, Nickoloff BJ: Discordant expression of Bcl-x and Bcl2 by keratinocytes in vitro and psoriatic keratinocytes in vivo. Am J Pathol 1995;146:1079–1088.
25.
Wrone-Smith T, Mitra S, Thompson CB, Jasty R, Castle VP, Nickoloff BJ: Keratinocytes derived from psoriatic plaques are resistant to apoptosis compared with normal skin. Am J Pathol 1997;151:1321–1322.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.